article thumbnail

JPM24: Riding label expansions and launches, AZ plots course toward 'industry-leading growth' by 2030

Fierce Pharma

In AZ's push to reach industry-leading growth by 2030, confidence is key, chief financial officer Aradhana Sarin said at the J.P. With a late-stage pipeline spanning more than 120 clinical trials and a firm grasp of five major disease areas, AstraZeneca appears confident heading into 2024. | Morgan Healthcare Conference.

Leads 267
article thumbnail

With Novo Nordisk, Eli Lilly and AstraZeneca leading the way, Big Pharma's sales will grow 4% annually through 2030: analysts

Fierce Pharma

With Novo Nordisk, Eli Lilly and AstraZeneca leading the way, Big Pharma's sales will grow 4% annually through 2030: analysts kdunleavy Mon, 10/02/2023 - 15:19

Leads 161
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Chinese companies lead ADC pipeline

Pharmaceutical Technology

Antibody drug conjugates (ADCs) are a rapidly growing therapeutic class that leading data and analytics company GlobalData forecasts will generate more than $45bn in revenue by 2030.

Leads 52
article thumbnail

OSD contract manufacturing market valued at $54.7 billion by 2030

European Pharmaceutical Review

billion by 2030, displaying a compound annual growth rate (CAGR) of 6.0 Leading companies in the oral solid dosage market are Catalent, Inc., Leading companies in the oral solid dosage market are Catalent, Inc., billion by 2030 appeared first on European Pharmaceutical Review.

article thumbnail

Endometriosis market projected to grow at a CAGR of 10% between 2020 and 2030

Pharmaceutical Technology

The endometriosis market is expected to grow from $1.05bn in 2020 to $2.72bn in 2030 at a compound annual growth rate (CAGR) of 10.0% The figure below summarises the endometriosis market growth across the 7MM from 2020 to 2030. At the end of 2030, the US will contribute approximately 81.3% of 7MM sales.

article thumbnail

U.S. Gastrointestinal Endoscopic Devices Market Growth (2022-2030)

Medico Reach

billion by 2030. This change will only lead to gastrointestinal endoscopies getting easier and saving time for both the doctors and the patient. Gastrointestinal Endoscopic Devices Market Growth (2022-2030) appeared first on MedicoReach. billion in 2021. The market is further expected to grow at a rate of 9.4% Final Thoughts.

article thumbnail

Construction of major radioligand therapy manufacturing site begins

European Pharmaceutical Review

The ATLab (Alpha Therapy Laboratory) Valenciennes in Onnaing, France, will produce lead-212 radioligand therapies. Facilitated by more than 3,000m² of floor space at the site, Orano Med shared that it is aiming to produce ten times this quantity by the end of the 2030. As a result, the project will receive public support of almost €3.8